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2012.07.0Abstract Purpose: The aim of the study is to evaluate the effect of a conformal irradiation in
short fractionation scheme of 49.5 Gy in 15 fractions in an overall time of 3 weeks, in terms of over-
all survival (OAS) and progression free survival (PFS) rates in brain glioma patients.
Patients and methods: A prospective study was conducted on 54 brain glioma patients and was car-
ried out in the Radiation Oncology Department, South Egypt Cancer Institute, Assiut University
during the period from April 2006 till June 2009. Patients were treated by hypofractionated confor-
mal irradiation (49.5 Gy/15 fractions/3 weeks).
Results: The median follow up was 23 months (range: 9–39 months). Two-year OAS and PFS rates
were 68% and 60%, respectively. In univariate analysis, age >50 years, poor performance status
[Karnofasky score of P40–670%], poor neuroperformance status of score III, high-grade tumor
[glioblastoma multiforme], and biopsy were all associated with statistically signiﬁcant reduction
in OAS and PFS rates. Multivariate analysis, showed that age >50 years and glioblastoma pathol-
ogy were the only independent prognostic factors that were associated with poor OAS (p= 0.003
and p= 0.004, respectively), and PFS (p= 0.027 and p= 0.011, respectively).
Conclusion: Hypofractionated conformal radiotherapy was as effective as the conventional radio-
therapy, with time sparing for patients, and for radiation oncology centers. Hypofractionated
radiotherapy may be considered the radiotherapy regimen of choice in clinical practice for patients
with gliomas.
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01Introduction
In patients with brain gliomas, radiation therapy delivered
postoperatively has been shown to increase survival by a few
months compared to surgery alone [1,2] with a 5-year survival
rate of 46% for irradiated low-grade astrocytoma patients.
Approximately 35% of treated patients with high-grade glio-
mas survive 1 year, but less than 20% will survive 2 years [3].and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
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should be of short duration and relatively devoid of side effects
[4]. Three-dimensional conformal radiotherapy treatment (3D-
CRT) planning and delivery has the general goal of conform-
ing the shape of a target volume, and limiting dose to critical
normal structures while increasing the tumor dose [5,6]. 3D-
CRT limits the dose to the hypothalamic and pituitary gland,
and reduces the risk of developing clinical hypopituitarism [7].
Our study tested the effect of a conformal irradiation in short
fractionation scheme of 49.5 Gy in 15 fractions in an overall
time of 3 weeks (in terms of OAS and PFS rates), which is bio-
logically equivalent to 60 Gy in fractions of 2 Gy according to
the linear quadratic model [8].
Patients and methods
The current phase II prospective study was conducted on 54
brain glioma patients and was carried out in the Radiation
Oncology Department, South Egypt Cancer Institute, Assiut
University during the period from April 2006 to June 2009.
The basis of sample size was collecting all patients who were
eligible during study period. The study included patients with
pathologically proven malignant glioma, Karnofsky perfor-
mance status scale of P40, and residual size after biopsy or
subtotal resection 65 cm in all dimensions. Every patient in
the study was subjected to history and physical examination
including neurological examination, hemogram, chemistry
proﬁle, brain MRI, and biopsy. Patients were treated by hyp-
ofractionated conformal irradiation with a total dose of
49.5 Gy given in 15 fractions through an overall period of
3 weeks (330 Gy/fraction). Informed consent was obtained
for all patients and the treatment decision was approved by
institutional review board at our center.
Radiation therapy technique
PTV was delineated on planning CT scan covering the contrast
enhanced zone plus 1 cm margin aiming at 49.5 Gy in 15 frac-
tions. Fixation of the patient’s head in treatment position was
done using a thermoplastic mask after the patient was central-
ized. Radio-opaque markers were placed over the mask along
laser beams over both tragus and midline to identify the refer-
ence isocenter. A lateral scout view is obtained, with scan slice
thickness of 5 mm. Patients were injected with urographin intra-
venous contrast, immediately before scanning. CT data were
then transferred by cable to the computer treatment planning
system, where gross target volume (GTV), clinical target vol-
ume (CTV), planning target volume (PTV) and critical struc-
tures (lens, optic nerve & chiasm, brain stem, spinal cord)
were determined on each slice. Beam’s eye view of PTVwas used
to choose beam directions and to shape ﬁelds with appropriate
shielding. Dose distributions were then calculated. A 3D plan
was done for each patient and was evaluated by isodose distri-
bution in each slice taking into consideration the International
Commission on Radiation Units and Measurements (ICRU50)
recommendations (heterogeneity should be kept with +7% &
5% of prescribed dose). Dose volume histogram (DVH) was
also done where the plan was considered acceptable if 95% of
PTVwas encompassed by 95%of prescribed tumor dose. Treat-
ment was given isocentrically using a linear accelerator. The
ﬁeld entry points are aligned using laser beams. Individualizedcustomized blocks were made according to the plan & checked
at simulator. All patients were treated by photon beams at
either 6 or 15 MV. Corticosteroid therapy (Dexamethasone am-
poules) was given at a starting dose of 16 mg/day and the dose
was adjusted upward or downward to reach the minimum dose
necessary to control neurological symptoms.
Statistical analysis
Progression free survival (PFS) was deﬁned as the interval
from enrollment of patients to the date of disease progression,
or death from any cause or to date of last follow up. Overall
survival (OAS) was deﬁned as the interval from enrollment
of patients to the date of death from any cause or to date of
last follow up. Progression free survival and OAS rates were
estimated using Kaplan–Meier method with Graphed Prism
program (version 5). The Log-rank test was used to examine
differences in PFS and OAS rates. Cox-regression multivariate
analysis was done to determine the independent prognostic
factors affecting survival. The p-values were double-sided
and 60.05 was the level of signiﬁcance.
Results
Patients’ characteristics
This prospective study included 54 patients with brain glioma.
Median age was 65 years (range: 30–75 years). Thirty-six pa-
tients (66.7%) were males and 18 (33.3%) were females with
male to female ratio of 2:1. The majority of our patients had
KPS of P40–670% (43 patients; 80%), and presented with
manifestations of increased intracranial tension (headache:
42 patients, 78% and vomiting; 38 patients, 70%). Twenty-
nine patients (54%) had neuroperformance status (NPS) of
score II, 43 patients (80%) had high grade glioma, 28 patients
(52%) showed temporoparietal lesions by imaging, and 29 pa-
tients (54%) underwent subtotal resection (Table 1).
Survival analysis
The median follow up was 23 months (range: 9–39 months).
Two-year OAS and PFS rates were 68% and 60%, respec-
tively. Patients with <50 years of age showed 2-year OAS
and PFS of 91%, and 77%, respectively compared to 47%
(p< 0.001, HR: 4.86, 95% CI: 2.12–11.13) and 44%
(p= 0.004, HR: 2.84, 95% CI: 1.40–5.75), respectively, for
older patients. For patients with KPS of >70%, 2-year OAS
and PFS rates were 100% (for both survival rates), compared
to 63% (p= 0.021, HR: 0.28, 95% CI: 0.09–0.82) and 55%
(p= 0.037, HR: 0.35, 95% CI: 0.14–0.89), respectively, for pa-
tients with KPS between 40% and 70%. The 2-year OAS rates
were 100%, 84%, and 26% for patients with NPS of scores I,
II, and III, respectively (p< 0.001), while the 2-year PFS rates
were 100%, 76%, and 18%, respectively (p 6 0.001). For pa-
tients with low grade glioma, 2-year OAS and PFS rates were
100% (for both survival rates), compared to 53% (p< 0.001,
HR: 1.99, 95% CI: 0.08–0.51), and 44% ((p< 0.001, HR:
0.26, 95% CI: 0.12–0.58), respectively, for those with high
grade glioma. Patients who underwent subtotal resection
showed 2-year OAS and PFS rates of 92.5% and 88%, respec-
tively, compared to 41.5% (p< 0.001, HR: 7.6, 95% CI: 3.07–
Table 1 Characteristics of 54 brain glioma patients.
Variables NO %
Age
<50 years 28 51.9
P50 years 26 48.1
Sex
Male 36 66.7
Female 18 33.3
Performance status
KPS: >70% 11 20.4
KPS: P40–670% 43 79.6
Neuroperformance status
I 6 11.1
II 29 53.7
III 19 35.2
Tumor site
Frontal 7 13
Parietal 8 14.8
Temporoparietal 28 51.9
Occipital 11 20.3
Pathological type
Fibrillary astrocytoma 11 20.4
Anaplastic astrocytoma 25 46.3
Glioblastoma multiforme 18 33.3
Surgical procedure
Biopsy 25 46.3
Subtotal resection 29 53.7
Clinical presentations
Headache 42 77.8
Vomiting 38 70.4
Seizure 23 42.6
Motor disturbance 24 44.4
Sensory disturbance 12 22.2
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respectively, for biopsied patients (Table 2 and Figs. 1–3).
Multivariate Cox regression analysis (Table 3) conﬁrmed
only the association between OAS and PFS and both age
(p= 0.003, HR: 3.12, 95% CI: 1.48–6.60, and p= 0.027,
HR: 2.50, 95% CI: 1.11–5.63, respectively) and pathology
(p= 0.004, HR: 5.79, 95% CI: 1.73–19.34, and p= 0.011,
HR: 4.82, 95% CI: 1.44–16.19, respectively).
There were minimal side effects to radiation therapy, in the
form of a transient worsening of pretreatment symptoms
(symptoms of increased ICT), early in the course of irradiation
which usually responds to a short term treatment course of
corticosteroids.
Discussion
In limited volume radiotherapy, for brain glioma patients, the
standard dose is 56–60 Gy in 28–30 fractions [9]. Dose escala-
tion above 60 Gy did not result in any improvement in disease
control or survival as shown by Scott et al. [10]. Nakagawa et
al. [11] reported 60–90 Gy high dose conformal radiotherapy
results of glioblastoma multiforme. The 1-year, 2-year, 5-year,
and 10-year overall survival rates were 75%, 42%, 20%, and
15%, respectively. But the high-dose conformal radiotherapydid not improve survival. Therefore, aggressive treatment
modalities did not add more beneﬁt to those patients, so a
trend to hypofractionated schedule of radiation therapy was
considered. Many studies were done on the short course of
radiation therapy to GBM like that of Heogler and Davey
[12], and Thomas et al. [13] who tried a palliative radiation
therapy course of 30 Gy/6 daily fractions and 30 Gy/10 daily
fractions, respectively. The median survival ranged between 4
and 8 months with an acceptable toxicity proﬁle. These results
were close to that described in conventional radiation therapy
[14,15]. Hulshof et al. [1] in a prospective randomized trial
compared 3 different fractionation schedules in 155 patients
with GBM: either 66 Gy/33 fractions (conventional method)
versus 40 Gy/8 fractions (5 Gy/fraction), or 28 Gy/4 fractions
(7 Gy per fraction), the median survival was 7, 5.6, and
6.6 months, respectively, so no signiﬁcant difference in survival
was noticed among the 3 groups, and the last 2 schedules were
well tolerated. These results were conﬁrmed by Chang et al.
[16] who reviewed the results of 59 cases of GBM treated with
hypofractionated schedule (50 Gy/20 fractions), 2.5 Gy per
fraction. Our study tested a hypofractionated schedule of radi-
ation therapy of 49.5 Gy in 15 fractions in an overall time of
3 weeks.
In the present study, the median follow-up was 23 months
(range: 9–39 months). The median survival was 33 months,
2-year OAS was 68% and the 2-year PFS was 60%. This is
comparable with Kurtman et al. [2] who studied the effect of
3-D conformal radiation therapy in patients with brain glio-
mas and found that the mean survival was 25.6 ± 2.7 months
and the 3 year survival rate was 55%.
Age, performance status, neuroperformance status, tumor
type, and extent of surgical resection, were analyzed in the cur-
rent study, as potential prognostic factors for overall survival
and progression free survival. In univariate analysis (Table 2),
age >50 years, poor performance status [KPS score of P40–
670%], poor neuroperformance status of score III, high-grade
tumor [glioblastoma multiforme], and biopsy were all associ-
ated with statistically signiﬁcant reduction in OAS and PFS
rates. This was in agreement with most of the reported studies
[2,17–19], where age, performance status and histology, are
considered as well known prognostic factors in malignant gli-
oma patients. In a retrospective Turkish study conducted on
60 patients of supratentorial malignant glial tumor, treated be-
tween November 1993 and June 1997 [17], univariate analysis
revealed a signiﬁcant impact of histology, Karnofesky perfor-
mance status, and age on survival. In another study, the extent
of surgical resection was also found to be an important prog-
nostic factor [18]. Therefore, stratiﬁcation of patients accord-
ing to prognostic factors might help to determine the
optimum treatment for individual patients. In the present
study, multivariate analysis (Cox regression model) of the
prognostic factors in patients with gliomas, showed that age
>50 years and glioblastoma pathology were the only indepen-
dent prognostic factors that were associated with poor OAS
(p= 0.003 and p= 0.004, respectively), and PFS (p= 0.027
and p= 0.011, respectively). This was matched with reported
studies, where multivariate analysis showed that age
>50 years [18,19], and glioblastoma pathology [20], were asso-
ciated with poor survival.
In the present study, the 2-year OAS rate of patients with
ﬁbrillary astrocytoma, was high (100%). This was matched
with most of the reported studies, where the 2-year survival
Table 2 Univariate analysis of prognostic factors affecting OAS and PFS rates in 54 brain glioma patients.
Factor Median OAS
(months)
2-year OAS
(%)
P value Median PFS
(months)
2-year PFS
(%)
P-value
Whole group (n = 54) 33 68 28 60
Age
>50 years (28) Undeﬁned 90.7 p< 0.001 32 77.1 p= 0.004
P50 years (26) 24 47 HR: 4.86, 95% CI;
2.12–11.13
23 43.9 HR: 2.84, 95% CI;
1.40–5.75
Performance status
KPS score >70% (11) Undeﬁned 100 p= 0.021 Undeﬁned 100 p= 0.037
KPS score P40–670%
(43)
29 63 HR: 0.28, 95% CI;
0.09–0.82
25 54.7 HR: 0.35, 95% CI;
0.14–0.89
Neuroperformance status
I (6) 38.5 100 p< 0.001 38 100 p< 0.001
II (29) 33 83.9 29 76
III (19) 20 25.8 18 18.1
Pathological type
LGG [FA (12)] 38.5 100 p< 0.001 38 100 p< 0.001
HGG (42) 25 53.2 HR: 0.19, 95% CI;
0.08–0.51
23 44.1 HR: 0.26, 95% CI;
0.12–0.58
Surgical procedure
Biopsy (25) 23 41.5 p< 0.001 22 31.9 p< 0.001
STR (29) 38 92.5 HR: 7.6; 95% CI;
3.07–18.84
36 88.1 HR: 5.3; 95% CI;
2.4–11.5
LGG, low grade glioma; HGG, high grade glioma; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; STR, subtotal resection.
Figure 1 Overall survival rates according to age in 54 patients
with gliomas.
Figure 2 Overall survival rates according to performance status
in 54 patients with gliomas.
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[21,22]. On the other hand, the current study, showed a 2-year
OAS of 18% for patients with glioblastoma multiforme. This
was consistent with two series, where the 2-year survival rates
of 17–20% in irradiated patients with glioblastoma multiforme
were reported [3,11,17]. However, other studies conducted on
patients with glioblastoma multiforme, showed higher 2-year
OAS rates which ranged between 26% and 35% [23–26]. The
superior survival rate in these studies may be explained on
the ground of different treatment schedules. In one of these
studies, hypofractionated dosing schedule using cyberknife
stereotactic radiotherapy was used [23]. The other reported
studies used radiotherapy plus concomitant and adjuvant tem-
ozolomide for glioblastoma patients [24–26].In conclusion, the hypofractionated conformal radiother-
apy was found to be as effective as the conventional radiother-
apy with no severe adverse effects. However, considering the
convenience of the short-course regimen in terms of time spar-
ing for patients, who can be treated in a few days, and the
advantage for radiation oncology centers, which are often
overloaded by long patient waiting lists, a short-course therapy
with the hypofractionated radiotherapy may be considered the
radiotherapy regimen of choice in clinical practice for patients
with gliomas.
Figure 3 Overall survival rates according to pathology in 54
patients with gliomas.
Table 3 Multivariate analysis (Cox regression model) of the
prognostic factors for OAS and PFS in patients with gliomas.
P-value HR 95% CI for HR
Variable aﬀectingOAS
Age 0.003 3.12 1.48–6.60
Pathology 0.004 5.79 1.73–19.34
Variable aﬀecting PFS
Age 0.027 2.50 1.11–5.63
Pathology 0.011 4.82 1.43–16.19
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